Amgen and sanofi-aventis Divest Manufacturing Assets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Amgen and sanofi-aventis Divest Manufacturing Assets


ePT--the Electronic Newsletter of Pharmaceutical Technology

Reflecting the ongoing manufacturing restructuring in the bio/pharmaceutical industry, Amgen and sanofi-aventis plan to sell manufacturing facilities to contract manufacturers. Amgen signed an agreement with Boehringer Ingelheim (BI), under which BI will acquire Amgen’s rights in and substantially all assets at Amgen’s Fremont, California, development and manufacturing facility. The transaction has been approved by the board of directors of each company and is expected to close in March 2011. Amgen’s Fremont facility currently employs approximately 360 employees and includes a 100,000-ft2 manufacturing facility, pilot plant, and process-development laboratories. 

“The technological expertise at Fremont and the state-of-the-art facility will enable us to further strengthen our global contract manufacturing business, including new biological entity process development and manufacturing efforts,” said Wolfram Carius, member of BI’s board of managing directors, in a Jan. 24, 2011, Amgen press release.

BI has been a contract manufacturer for Amgen for more than 10 years. Amgen obtained the Fremont facility through its 2006 acquisition of the biopharmaceutical company Abgenix. Amgen will continue to have a presence in the San Francisco Bay area through its South San Francisco facility, one of the company’s research centers.

sanofi-aventis divests Madrid facility
In other news, sanofi-aventis agreed to sell its plant at Avenida de Leganes in Alcorcon-Madrid, Spain, to the contract development and manufacturing organization Famar. All employees of the plant will be transferred. The plant produces solid and sterile dosage forms, including freeze-dried products.

Under the deal, which is expected to close in the second quarter of 2011, sanofi-aventis will continue to source certain products from the site under a supply agreement with Famar, which also will also develop the plant for external manufacturing activities. Famar will expand the plant’s sterile capacities and offerings. Famar had earlier acquired a sanofi plant in L’Aigle, France, in 2001.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here